LEDOXANTRONE, a benzothiopyranoindazole, is an intercalating agent. Its mechanism of action is probably due to DNA helicase blockade. It was under development for the treatment of prostate and ovarian cancers.

Ioflubenzamide I-131 (also known as 131-I-MIP-1145) is a radiolabeled iodobenzamide derivative developed by Molecular Insight Pharmaceuticals, Inc for metastatic melanoma treatment. The benzamide moiety of Ioflubenzamide I-131 binds to melanin, selectively delivering a cytotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. In human melanoma xenografts, Ioflubenzamide I-131 exhibited diffuse tissue distribution and washout from all tissues except melanin-expressing tumors. The administration of Ioflubenzamide I-131 at 25 MBq in single or multiple doses significantly reduced SK-MEL-3 tumor growth, with multiple doses resulting in tumor regression and durable response for over 125 days. Unfortunately Phase I clinical trial was terminated by unknown reason.

Tocofibrate is a peroxisomotropic ester compound consisting of both clofibric acid and alpha-tocopherol. Tocofibrate is a hypocholesterolemic drug. Lowering activity of tocofibrate in cholesterol level in blood was no less than that of clofibrate in rats fed high-fat cholesterol diet. In view of the fact that only a fraction of tocofibrate is not hydrolyzed in the liver 24-hr following oral administration, it was reasonable to assume that tocofibrate exerts its effect in an unaltered state rather than as a result of hydrolysis to clofibric acid and alpha-tocopherol. The distribution of tocofibrate clearly differs from that of both clofibrate and alpha-tocofibrate is primarily associated with its effect upon liver peroxisomes. Tocofibrate acts upon peroxisomes to lower plasma lipid levels.

Rumenic acid is the major conjugated linoleic acid (CLA), probably because of successive desaturation and chain elongation and can be considered as the principal dietary form. In experiments on rodents was shown that rumenic acid possessed the protective effect against colitis, which was associated with the activation of the Nrf2 pathway.

(E)-Tetrachlorovinphos is an (E)- isomer of Tetrachlorovinphos. Tetrachlorovinphos is an organophosphate cholinesterase inhibitor that is used as an insecticide. Tetrachlorvinphos was introduced and first used commercially in 1966 in the USA. Tetrachlorvinphos was originally registered for use on various food crops, livestock, pet animals. Tetrachlorvinphos is applied dermally to livestock to control flies and mites. It is used as an oral larvicide in cattle, hog, goats and horses; in cattle ear tags to control flies; in cattle feedlots; in poultry dust boxes to control poultry mites; and in poultry houses. Tetrachlorvinphos also is used in pet sleeping areas and pet flea collars and to control flies around refuse sites, recreational areas, and for general outdoor treatment. Tetrachlorvinphos can cause cholinesterase inhibition in humans; that is, it can overstimulate the nervous system causing nausea, dizziness, confusion, and at very high exposures (e.g., accidents or major spills), respiratory paralysis and death. In 2014, the Natural Resources Defense Council (NRDC) filed a lawsuit against the United States Environmental Protection Agency (EPA) seeking EPA to respond to NRDC’s 2009 petition to ban tetrachlorvinphos in common pet flea treatment products. Tetrachlorvinphos is reportedly registered for use in Canada, South Africa, and Australia.

Quindecamine (also known as UCL-1407) is quinaldine derivative with antibiotic and fungicidal activity. Treatment of rats and mice with Quindecamine (250 mg/kg/ day) each day for 4 weeks followed by 500 mg/kg/day for 2 more weeks reduced spontaneous motility and body weight but produced no pathological abnormalities of the various organs studied. In vitro, the drug showed very good activity against Staphylococcus aureus, Streptococcus hemolyticus, Candida albicans, Trichophyton mentagrophytes, and T. vaginalis. The drug had very good activity in 180 human subjects with various bacterial and mycotic diseases of the skin and mucosa when applied as a 1% salve.

Tridecanoic acid is a 13-carbon saturated fatty acid found in dairy products and also as a product of anaerobic biodegradation of n-hexadecane. It has been identified as a substrate of phospholipase A2. Saturated fatty acids with carbon chain lengths of C12 to C14 activated the alpha-, beta-, gamma-, and epsilon-subspecies of the protein kinase C, and this activation was synergistic with that by diacylglycerol. Tridecanoic acid(C13) was most effective among the saturated fatty acids examined.

Cetoxime is an aromatic amine patented by Boots Pure Drug Co. as antihistaminic drug

Isoindoline pazinaclone (also known as DN-2327), a partial agonist at GABAA benzodiazepine receptors, produced anxiolytic, taming and anti-convulsive effects. This neuropsychiatric drug was involved in phase II clinical trial for patients with generalized anxiety disorder. However, this study was discontinued.

DDP-225 (also known as MCI-225), a thienopyrimidine analog, is a selective noradrenaline reuptake inhibitor with serotonin receptor antagonism. It shows antidepressant-like properties in animal models. MCI-225 could be useful in the treatment of attentional deficits and related cognitive dysfunctions in psychiatric disorders.